STOML2 and neoplasm: To investigate the role of STOML2 in response to anti-angiogenic treatment in vivo, immunodeficient BALB/c nude mice bearing STOML2-overexpressing, STOML2-silenced or control HCT116 tumor xenografts were treated with control solvent or bevacizumab antibody.